Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.42 USD
+0.15 (6.61%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.41 -0.01 (-0.41%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth F Momentum F VGM
Earnings News For RGLS
-
Regulus: Q4 Earnings Snapshot
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
-
Regulus: Q3 Earnings Snapshot
-
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
-
Regulus: Q2 Earnings Snapshot
-
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
-
Regulus: Q1 Earnings Snapshot
-
Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
-
Regulus: Q4 Earnings Snapshot
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Updates
-
Regulus: Q3 Earnings Snapshot
-
Regulus Therapeutics Reports Third Quarter 2022 Financial Results and Recent Updates
-
Regulus: Q2 Earnings Snapshot
-
Regulus Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates
-
Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates
-
Analysts Estimate Regulus (RGLS) to Report a Decline in Earnings: What to Look Out for
-
Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates
-
Regulus (RGLS) Reports Q1 Loss, Misses Revenue Estimates
-
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Will Regulus (RGLS) Report Negative Q4 Earnings? What You Should Know
-
Regulus (RGLS) Reports Q3 Loss, Tops Revenue Estimates
-
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
-
Regulus (RGLS) Reports Q2 Loss, Lags Revenue Estimates
-
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
-
Regulus (RGLS) Expected to Beat Earnings Estimates: Should You Buy?